Tolterodine
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H318889

CAS#: 124937-51-5 (free base)

Description: Tolterodine is an antimuscarinic drug that is used for symptomatic treatment of urinary incontinence.


Chemical Structure

img
Tolterodine
CAS# 124937-51-5 (free base)

Theoretical Analysis

Hodoodo Cat#: H318889
Name: Tolterodine
CAS#: 124937-51-5 (free base)
Chemical Formula: C22H31NO
Exact Mass: 325.24
Molecular Weight: 325.488
Elemental Analysis: C, 81.18; H, 9.60; N, 4.30; O, 4.92

Price and Availability

Size Price Availability Quantity
5mg USD 250
10mg USD 450
25mg USD 950
Bulk inquiry

Related CAS #: 124937-51-5 (free base)   124937-52-6 (tartrate)    

Synonym: Tolterodine, Detrol, Detrusitol, PHA-686464B

IUPAC/Chemical Name: 2-[(1R)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol

InChi Key: OOGJQPCLVADCPB-HXUWFJFHSA-N

InChi Code: InChI=1S/C22H31NO/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24/h6-12,15-17,20,24H,13-14H2,1-5H3/t20-/m1/s1

SMILES Code: OC1=CC=C(C)C=C1[C@@H](C2=CC=CC=C2)CCN(C(C)C)C(C)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 325.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Gacci M, Sebastianelli A, Salvi M, Schiavina R, Brunocilla E, Novara G, De Nunzio C, Tubaro A, Oelke M, Gravas S, Carini M, Serni S. Tolterodine in the Treatment of Male LUTS. Curr Urol Rep. 2015 Sep;16(9):60. doi: 10.1007/s11934-015-0531-9. Review. PubMed PMID: 26149965.

2: Gacci M, Novara G, De Nunzio C, Tubaro A, Schiavina R, Brunocilla E, Sebastianelli A, Salvi M, Oelke M, Gravas S, Carini M, Serni S. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review. BMC Urol. 2014 Oct 27;14:84. doi: 10.1186/1471-2490-14-84. Review. PubMed PMID: 25348235; PubMed Central PMCID: PMC4230346.

3: Angulo JC, Valpas A, Rejas J, Linden K, Kvasz M, Snedecor SJ. Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland. Clin Drug Investig. 2014 May;34(5):297-307. doi: 10.1007/s40261-014-0178-1. Review. PubMed PMID: 24567280.

4: Medhi B, Mittal N, Bansal D, Prakash A, Sarangi SC, Nirthi B. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review. Indian J Physiol Pharmacol. 2013 Oct-Dec;57(4):343-53. Review. PubMed PMID: 24968572.

5: Elterman DS, Chughtai B, Kaplan SA, Barkin J. Tolterodine for the treatment of urge urinary incontinence. Expert Opin Pharmacother. 2013 Oct;14(14):1987-91. doi: 10.1517/14656566.2013.823158. Epub 2013 Jul 26. Review. PubMed PMID: 23885788.

6: Omotosho T, Chen CC. Update on tolterodine extended-release for treatment of overactive bladder. Open Access J Urol. 2010 Nov 23;2:185-91. doi: 10.2147/OAJU.S7232. Review. PubMed PMID: 24198627; PubMed Central PMCID: PMC3818890.

7: Chung DE, Te AE. Tolterodine extended-release for overactive bladder. Expert Opin Pharmacother. 2009 Sep;10(13):2181-94. doi: 10.1517/14656560903167965. Review. PubMed PMID: 19663610.

8: Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):4481-9. Review. PubMed PMID: 19835561.

9: Ulahannan D, Wagg A. The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly. Clin Interv Aging. 2009;4:191-6. Epub 2009 May 14. Review. PubMed PMID: 19503781; PubMed Central PMCID: PMC2685240.

10: Bolge SC, McDonnell DD, Chen A, Wan GJ. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder. Curr Med Res Opin. 2007 Aug;23(8):1903-12. Review. PubMed PMID: 17610806.

11: Rovner ES. Tolterodine for the treatment of overactive bladder: a review. Expert Opin Pharmacother. 2005 Apr;6(4):653-66. Review. PubMed PMID: 15934891.

12: Garely AD, Burrows L. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Drug Saf. 2004;27(13):1043-57. Review. PubMed PMID: 15471509.

13: Wefer J, Truss MC, Jonas U. Tolterodine: an overview. World J Urol. 2001 Nov;19(5):312-8. Review. PubMed PMID: 11760779.

14: Crandall C. Tolterodine: a clinical review. J Womens Health Gend Based Med. 2001 Oct;10(8):735-43. Review. PubMed PMID: 11703885.

15: Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging. 2001;18(4):277-304. Review. PubMed PMID: 11341475.

16: Guay DR. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Pharmacotherapy. 1999 Mar;19(3):267-80. Review. PubMed PMID: 10221366.

17: Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs. 1998 Jun;55(6):813-20; discussion 821-2. Review. PubMed PMID: 9617596.

18: Salvatore S, Serati M, Bolis P. Tolterodine for the treatment of overactive bladder. Expert Opin Pharmacother. 2008 May;9(7):1249-55. doi: 10.1517/14656566.9.7.1249. Review. PubMed PMID: 18422481.

19: Kanofsky JA, Nitti VW. Tolterodine for treatment of overactive bladder. Urol Clin North Am. 2006 Nov;33(4):447-53, viii. Review. PubMed PMID: 17011380.

20: Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother. 2001 Oct;2(10):1685-701. Review. PubMed PMID: 11825311.